Idogen AB’s (“Idogen”) Annual General Meeting on May 11, 2021, resolved that the company shall have a Nomination Committee comprising one representative for each of the three largest shareholders in terms of number of votes based on the ownership statistics on August 31, 2021, which the company receives from Euroclear Sweden AB. In accordance with the resolution by the Annual General Meeting on the guidelines for the Nomination Committee, the Chairman of the Board Agneta Edberg has prepared a list of the names of the three largest shareholders. In the case of owners who did not wish to be represented on the Nomination Committee, the request was passed on to the next largest owner.
The Nomination Committee, comprising Tobias Ekman, Per Eliasson and Leif G Salford (representing Leif G Salford and Hans-Olov Sjögren) was convened. Tobias Ekman was appointed Chairman of the Nomination Committee. Chairman of the Board Agneta Edberg was co-opted, alongside CFO Ingvar Karlsson (secretary). The Nomination Committee has therefore initiated the preparation of proposals for the 2021 Annual General Meeting.
The Nomination Committee will prepare proposals on the following matters:
- proposal for Chairman of the Annual General Meeting;
- proposal regarding the number of Board members and the number of auditors;
- proposal for fees for Board members;
- proposal for fee to auditors;
- proposal for election of Chairman of the Board and other Board members, as well as election of auditors; and
- proposal on guidelines to appoint members of the Nomination Committee and on the Nomination Committee’s assignment.
Lund November 3, 2021
Idogen AB (publ)
The information was submitted for publication, through the agency of the contact persons set out above, on 3 November 2021, 08:48 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com